RxDoctor Payments Data

Robert Price, MD

Internal Medicine · Augusta, GANPI 1003911587

Payments from drug & device makers

$10,020in general payments, 2019–2025

Across 658 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • AstraZeneca$832
  • Otsuka America Pharmaceutical, Inc.$619
  • Amgen$604
  • Lilly USA, LLC$560
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$9,88999%
  • Education$1311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)103$1,310
Novo Nordisk99$1,262
AstraZeneca49$832
Otsuka America Pharmaceutical, Inc.29$619
Amgen(2 entities)50$604
Lilly USA, LLC46$560
Abbott22$415
Pfizer23$372
Amarin Pharma, Inc.25$354
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC22$342
Bayer18$309
Dexcom, Inc.16$306
GSK15$226
Novartis12$207
Boehringer Ingelheim12$203
Organogenesis Inc.4$173
Astellas Pharma US Inc5$159
Boston Scientific7$139
Johnson & Johnson7$105
Mylan Specialty L.p.5$97
Exact Sciences6$92
Harmony Biosciences LLC5$88
Takeda Pharmaceuticals U.S.A., Inc.7$85
Merck5$79
Axsome Therapeutics, Inc.4$76
Biohaven Pharmaceutical Holding Company Ltd.4$70
Lundbeck LLC3$64
Supernus Pharmaceuticals, Inc.4$55
Eisai Inc.4$52
Ironwood Pharmaceuticals, Inc3$50
Sumitomo Pharma America, Inc.3$49
Kowa Pharmaceuticals America, Inc.3$39
Idorsia Pharmaceuticals US Inc2$35
Scilex Pharmaceuticals Inc.2$35
Globus Medical1$34
Esperion Therapeutics, Inc.2$34
Adlon Therapeutics L.p.2$33
Biohaven Pharmaceuticals, Inc.2$33
Irhythm Technologies, Inc.1$33
Phathom Pharmaceuticals, Inc.2$30
Teva Pharmaceuticals USA, Inc.2$23
Inspire Medical Systems, Inc.1$22
Corcept Therapeutics1$21
Vanda Pharmaceuticals Inc.1$19
Abiomed1$18
Jazz Pharmaceuticals Inc.1$18
Global Blood Therapeutics, Inc.1$18
Cequr Corporation1$17
Paratek Pharmaceuticals, Inc.1$15
Antares Pharma, Inc.1$15
Resmed Corp1$15
Sanofi-aventis U.S. LLC1$15
Avanir Pharmaceuticals, Inc.1$15
Daiichi Sankyo Inc.1$15
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$15
Edwards Lifesciences1$15
Genentech USA, Inc.1$14
Radius Health, Inc.1$14
Currax Pharmaceuticals LLC1$12
Upsher-smith Laboratories LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,020 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$229,675
Medicare patients
396
Services billed
8,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide136$198,668
MounjaroTirzepatide140$177,304
JardianceEmpagliflozin147$121,013
EliquisApixaban142$102,690
FarxigaDapagliflozin Propanediol107$94,958
JanuviaSitagliptin Phosphate82$68,829
Repatha SureclickEvolocumab95$59,036
RybelsusSemaglutide45$54,216
LinzessLinaclotide77$48,717
VraylarCariprazine Hcl33$48,671
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$43,528
Breztri AerosphereBudesonide/Glycopyr/Formoterol46$30,692
XareltoRivaroxaban27$23,351
QuliptaAtogepant12$21,276
TrulicityDulaglutide21$20,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog Mix 70-30$1,262$257,373193 claims
Lilly USA, LLCMounjaro, Trulicity$560$197,839161 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$203$149,668181 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$832$140,431191 claims
AbbVieLinzess, Vraylar, Qulipta, Synthroid$1,310$126,207218 claims
PfizerEliquis$372$102,690142 claims
MerckJanuvia, Belsomra$79$84,200117 claims
GSKTrelegy Ellipta, Shingrix$226$47,93961 claims
Johnson & JohnsonXarelto$105$23,35127 claims
Astellas Pharma US IncMyrbetriq$159$20,51028 claims
NovartisEntresto$207$11,63413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →